JP6266506B2 - Ｈｓｐ９０阻害物質 - Google Patents

Ｈｓｐ９０阻害物質 Download PDF

Info

Publication number
JP6266506B2
JP6266506B2 JP2014503994A JP2014503994A JP6266506B2 JP 6266506 B2 JP6266506 B2 JP 6266506B2 JP 2014503994 A JP2014503994 A JP 2014503994A JP 2014503994 A JP2014503994 A JP 2014503994A JP 6266506 B2 JP6266506 B2 JP 6266506B2
Authority
JP
Japan
Prior art keywords
another embodiment
amino
methyl
pharmaceutically acceptable
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014503994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510148A5 (enExample
JP2014510148A (ja
Inventor
ウェイリン スン，
ウェイリン スン，
トニー タルドーン，
トニー タルドーン，
パラブ パテル，
パラブ パテル，
ガブリエラ チオシス，
ガブリエラ チオシス，
Original Assignee
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン − ケッタリング インスティチュート フォー キャンサー リサーチ, スローン − ケッタリング インスティチュート フォー キャンサー リサーチ filed Critical スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Publication of JP2014510148A publication Critical patent/JP2014510148A/ja
Publication of JP2014510148A5 publication Critical patent/JP2014510148A5/ja
Application granted granted Critical
Publication of JP6266506B2 publication Critical patent/JP6266506B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014503994A 2011-04-05 2012-04-05 Ｈｓｐ９０阻害物質 Expired - Fee Related JP6266506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472061P 2011-04-05 2011-04-05
US61/472,061 2011-04-05
PCT/US2012/032371 WO2012138894A1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016228549A Division JP2017061540A (ja) 2011-04-05 2016-11-25 Ｈｓｐ９０阻害物質

Publications (3)

Publication Number Publication Date
JP2014510148A JP2014510148A (ja) 2014-04-24
JP2014510148A5 JP2014510148A5 (enExample) 2015-05-21
JP6266506B2 true JP6266506B2 (ja) 2018-01-24

Family

ID=48166734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503994A Expired - Fee Related JP6266506B2 (ja) 2011-04-05 2012-04-05 Ｈｓｐ９０阻害物質

Country Status (11)

Country Link
US (2) US9346808B2 (enExample)
EP (1) EP2694505B1 (enExample)
JP (1) JP6266506B2 (enExample)
KR (1) KR102010222B1 (enExample)
CN (1) CN103582642B (enExample)
AU (1) AU2012240077C1 (enExample)
BR (1) BR112013025634A2 (enExample)
CA (1) CA2832530C (enExample)
EA (1) EA201391334A1 (enExample)
MX (1) MX360390B (enExample)
WO (1) WO2012138894A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
KR102129420B1 (ko) 2009-10-07 2020-07-03 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
EP3208615B1 (en) * 2011-07-08 2019-10-09 Sloan Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2015023976A2 (en) 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
JP6491214B2 (ja) * 2013-12-23 2019-03-27 メモリアル スローン ケタリング キャンサー センター 放射性標識のための方法および試薬
JP6835709B2 (ja) * 2014-09-17 2021-02-24 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
US20210161902A1 (en) * 2017-06-23 2021-06-03 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670348B1 (en) 1997-05-14 2003-12-30 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
CA2370007A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
EP1335920B1 (en) 2000-11-02 2013-04-03 Sloan-Kettering Institute For Cancer Research Compositions containing purine derivatives for binding to hsp90
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
AU2002356922A1 (en) 2001-11-09 2003-05-26 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
MXPA04008312A (es) 2002-02-28 2004-11-26 Astrazeneca Ab Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos.
EP1620564A4 (en) 2003-04-18 2008-03-12 Cytovia Inc METHODS FOR TREATING DISEASES INDUCING APOPTOSIS INDUCTION AND SCREENING ASSAYS
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
AU2006331917A1 (en) * 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
NZ572600A (en) 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
FR2906824B1 (fr) 2006-10-09 2008-12-26 Roger Mondelin Sas Soc Par Act Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
NZ579635A (en) 2007-03-20 2011-07-29 Curis Inc Fused amino pyridine as hsp90 inhibitors
US20100240656A1 (en) * 2007-07-12 2010-09-23 Oryzon Genomics, S.A. Compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
NZ586129A (en) * 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
CA3017874A1 (en) 2009-01-16 2010-07-22 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
EP2453989B1 (en) * 2009-07-17 2019-10-23 Cleanspace IP Pty Ltd. Respirator
GB0914543D0 (en) * 2009-08-20 2009-09-30 Ge Healthcare Ltd Radioiodination method
KR102129420B1 (ko) 2009-10-07 2020-07-03 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
KR101984480B1 (ko) 2011-04-05 2019-05-31 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2015023976A2 (en) 2013-08-16 2015-02-19 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2832530C (en) 2021-02-16
BR112013025634A2 (pt) 2016-07-19
NZ616758A (en) 2016-01-29
MX360390B (es) 2018-10-31
KR20140062429A (ko) 2014-05-23
KR102010222B1 (ko) 2019-08-13
MX2013011532A (es) 2014-08-22
AU2012240077B2 (en) 2017-04-20
EP2694505A1 (en) 2014-02-12
US20140088121A1 (en) 2014-03-27
CN103582642B (zh) 2021-05-11
AU2012240077C1 (en) 2017-08-10
US9926321B2 (en) 2018-03-27
EP2694505B1 (en) 2022-04-27
EA201391334A1 (ru) 2014-06-30
US9346808B2 (en) 2016-05-24
AU2012240077A1 (en) 2013-10-31
US20160264577A1 (en) 2016-09-15
JP2014510148A (ja) 2014-04-24
CN103582642A (zh) 2014-02-12
WO2012138894A4 (en) 2012-12-06
WO2012138894A1 (en) 2012-10-11
CA2832530A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
JP6266506B2 (ja) Ｈｓｐ９０阻害物質
JP5961683B2 (ja) Ｈｓｐ９０阻害物質
AU2009231978C1 (en) Purine derivatives as A3 adenosine receptor- selective agonists
KR20210134738A (ko) Jak 억제제 및 그 제조방법과 의약분야에서의 응용
CA3077267C (en) Fused heteroaryl ring derivatives useful as a2a receptor inhibitor
JP2017061540A (ja) Ｈｓｐ９０阻害物質
HK1194376A (en) Hsp90 inhibitors
HK1194376B (en) Hsp90 inhibitors
NZ616758B2 (en) Hsp90 inhibitors
HK1194375B (en) Hsp90 inhibitors
HK1194375A (en) Hsp90 inhibitors
JP2022538119A (ja) １－（２－（（（（ｔｒａｎｓ）－３－フルオロ－１－（３－フルオロピリジン－２－イル）シクロブチル）メチル）アミノ）ピリミジン－５－イル）－１Ｈ－ピロール－３－カルボキサミドの多形
NZ616890B2 (en) Hsp90 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170110

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170830

R150 Certificate of patent or registration of utility model

Ref document number: 6266506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees